drug development
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 people. Also written “drug-development”; the spellings share this page.
Related tags
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Armando Santoro Head of the Medical Oncology and Hematology Unit; Full Professor of Medical Oncology, Humanitas University · IRCCS Humanitas Research Hospital Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs. | Hodgkin lymphoma, Diffuse large B-cell lymphoma, Hepatocellular carcinoma | none | clinician-scientist, leadership, lymphoma | ||
Daniel D. Von Hoff Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute · Translational Genomics Research Institute (TGen) Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone. | Pancreatic ductal adenocarcinoma | none | pancreatic, early-phase | ||
Goh Boon Cher Deputy Director (Research) · National University Hospital / National University Cancer Institute, Singapore Senior medical oncologist and translational researcher who leads research at NCIS, with a long record in experimental therapeutics and head and neck cancer. | Head and neck squamous cell carcinoma, Nasopharyngeal carcinoma | none | leadership, clinician-scientist, head and neck cancer | ||
Julian Adams President and CEO · Stand Up To Cancer Medicinal chemist who led the discovery of the proteasome inhibitor bortezomib and now heads Stand Up To Cancer as President and CEO. | Multiple myeloma | none | leadership, research funding | ||
Patrick Mehlen Director of Fundamental and Translational Research and of the Cancer Research Center of Lyon (CRCL) · Centre Léon Bérard Cancer biologist who discovered the dependence-receptor concept and took netrin-1 blockade from bench to clinical trials at Centre Léon Bérard. | Endometrial cancer | none | leadership, clinician-scientist, cancer biology | ||
Shivaani Kummar Chief Scientific and Academic Officer, Knight Cancer Group and Director, Knight Cancer Institute · OHSU Knight Cancer Institute Drug development oncologist who directs the OHSU Knight Cancer Institute. | none | none | leadership, clinician-scientist, precision oncology | ||
Toshihiko Doi Director, Department of Experimental Therapeutics, National Cancer Center Hospital East · National Cancer Center Hospital Led the first-in-human study of trastuzumab deruxtecan and runs one of Asia's most productive phase 1 units. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | leadership, clinician-scientist, gastric cancer | ||
Yasuhiro Fujiwara Chief Executive · Pharmaceuticals and Medical Devices Agency Medical oncologist who heads Japan's Pharmaceuticals and Medical Devices Agency, the national drug and device regulator. | none | none | leadership, regulation |
